What are the top healthcare market research companies in the USA?▾
The healthcare market research companies US affiliates shortlist in 2026 are BioNixus (primary account-level and SKU-level fieldwork), IQVIA (syndicated Rx and RWE), Ipsos Healthcare (multi-country HCP and patient studies), Kantar (consumer-health brand tracking), M3 Global Research (online physician panels), Clarivate/DRG (secondary intelligence), and Research Partnership/Inizio Ignite (healthcare-dedicated agency). Brief BioNixus when IQVIA or NielsenIQ cannot name the hospital, city, or SKU. Keep syndicated contracts for national measurement.
Is BioNixus a replacement for IQVIA or NielsenIQ?▾
No. Complementary. Keep IQVIA for national prescription audits and claims/RWE platforms. Keep NielsenIQ for national retail and FMCG measurement. Brief BioNixus for named accounts, cities, SKUs, HCP ATU, pharmacy mystery shop, and competitor intelligence those dashboards cannot cut. Most US affiliates run a syndicated contract and a primary firm together. See the IQVIA alternative and Nielsen alternative pages for the same model.
When should a US affiliate brief primary research?▾
Brief primary research when the decision names an account, city, SKU, or traditional-trade channel the dashboard does not sell — for example a hospital or IDN win/loss, a city launch, an HCP ATU, a pharmacy mystery shop, or brand-versus-competitor facing at named accounts. Keep syndicated IQVIA or NielsenIQ when you need a national Rx or retail total. See account-level market research, HCP ATU study, pharmacy mystery shopper, and pharmaceutical competitor intelligence for the study types.
How much does a USA primary study cost?▾
BioNixus publishes typical 2026 planning bands on the pricing page (/pricing): $10,000–$75,000 USD for a single-country study and $25,000–$120,000 USD for a multi-country study. Qualitative KOL or payer work sits toward the lower end. Mixed-method physician surveys and specialist HCP samples sit toward the upper end. These are planning bands, not a quote, and not a comparison to unpublished NielsenIQ or IQVIA subscription fees. Request a USA research proposal for a scoped figure.
How fast is a proposal?▾
A USA research proposal is typically ready within 48 hours of a brief. Call +1 888 465 5557 (US), +44 7727 666682 (UK), or +20 120 688 2323 (MEA), or email admin@bionixus.com. Use the form on this page with a therapy area, the decision you need to make, and whether you already buy IQVIA or NielsenIQ.
How does the IRA affect US healthcare market research?▾
The Inflation Reduction Act Medicare price negotiation (first cohort effective January 2026) changes commercial strategy for products with Medicare exposure. Maximum Fair Prices reshape PBM rebate talks and commercial formulary positioning. Primary research maps how physicians, PBMs, and plan directors respond — it does not replace IQVIA’s national Rx feed. BioNixus layers IRA context into payer and HCP briefs when the product is exposed.
Which research firm is best for IRB-compliant HCP research across the USA?▾
BioNixus designs US HCP and patient studies under 45 CFR Part 46 / Common Rule and HIPAA/HITECH, with documented informed consent and de-identified reporting. Programs cover physicians and KOLs at Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, and Massachusetts General Hospital, plus community IDN networks. M3 is the faster online-panel option when you only need a digital questionnaire.
Can a single research firm cover Northeast, South, Midwest, and West Coast?▾
Yes. BioNixus fields multi-region US healthcare studies covering Northeast (Boston, New York, Philadelphia), South (Houston, Atlanta, Miami), Midwest (Chicago, Cleveland, Minneapolis), and West Coast (San Francisco, Los Angeles, Seattle). Programs are stratified when prescribing, payer mix, or GPO contracting differs by region — a single national average rarely answers an account-level brief.